Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
about
Secukinumab for ankylosing spondylitis and psoriatic arthritisSecukinumab: A Review in Psoriatic Arthritis.Secukinumab for the treatment of psoriatic arthritis.Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.The role of IL-17 in the treatment of psoriatic arthritis.Inflammatory osteolysis: a conspiracy against bone.Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1.Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities.Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions.The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trialThe Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and FutureThe role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis
P2860
Q28071474-7A595D00-90FF-4FAA-97BB-8660F4C18254Q38864743-6E45874D-B7B7-4DFA-BC5F-5BA9ABAEF55AQ38934405-1DC47C73-AD76-47BB-A559-DBEF9B74933FQ38985676-2A150B2F-94C6-4F25-8A9D-7EAB9867A192Q38998373-FB94A071-AE46-4F5C-9138-8A12C1752C0EQ39293096-43F27609-F04B-4374-AA9F-03FA6ED25C7FQ39343563-BE82BAAE-8FC9-472E-992E-60E48AA5BAB0Q47148249-397EEFE6-9D58-43E9-9FC7-6FDBCFBD6D87Q47550260-7D615FBD-40F0-4AE1-A930-5B27AE237410Q47704613-11C69CD5-FB26-4AE6-93E6-FB7DBDD66C84Q47734526-D55B8AC7-A4FE-4185-8E72-1B1DD1F99A08Q48283709-3E11C1AE-E356-46EF-9C9E-F4CC961B924AQ50099588-91DEFCC3-B395-4404-9ECC-F7EB03B11CC3Q57169747-BAA4CABB-A615-4922-B8A7-101545DB5391Q58567074-2722C1D1-AA1A-4D59-A092-3B1198BDB3B3Q58761666-F322A824-6004-4E82-BA65-336615B25E9C
P2860
Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en-gb
type
label
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en-gb
prefLabel
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en-gb
P2093
P2860
P356
P1154
2-s2.0-84977760286
P1476
Brief Report: Secukinumab Prov ...... of Active Psoriatic Arthritis.
@en
P2093
Greg Ligozio
Hanno B Richards
Iain B McInnes
Luminita Pricop
Philip J Mease
Robert B Landewé
Shephard Mpofu
P2860
P304
P356
10.1002/ART.39685
P5530
P577
2016-03-25T00:00:00Z
P6179
1035174810